HN2002000253A - Uso de una combinacion de compuestos en un inhalador de polvo seco - Google Patents
Uso de una combinacion de compuestos en un inhalador de polvo secoInfo
- Publication number
- HN2002000253A HN2002000253A HN2002000253A HN2002000253A HN2002000253A HN 2002000253 A HN2002000253 A HN 2002000253A HN 2002000253 A HN2002000253 A HN 2002000253A HN 2002000253 A HN2002000253 A HN 2002000253A HN 2002000253 A HN2002000253 A HN 2002000253A
- Authority
- HN
- Honduras
- Prior art keywords
- formulation
- dry powder
- powder inhaler
- compound combination
- lung
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 210000004072 lung Anatomy 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Descrito es una formulación que comprende inhalado 9-ciclopentil-5 ,6-dihidro-7-etil-3-(tien-2-il)-9H-pirazolo [3,4-c] 1,2,4-triazolo [4, 3-alfa] piridina o una sal farmacéuticamente aceptable del mismo, en el que la formulación es capaz de suministrar el compuesto como partículas sólidas en el pulmón. Las partículas son de menos de 20 micrómetros de diámetro y la formulación es capaz de ser entregado al pulmón mediante un inhalador de polvo seco. Esta formulación inhalada se puede utilizar en la fabricación de un medicamento para el tratamiento de una enfermedad tratable mediante la inhibición de PDE4, tales como una enfermedad respiratoria, por ejemplo asma o enfermedad pulmonar obstructiva crónica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0122031.8A GB0122031D0 (en) | 2001-09-12 | 2001-09-12 | Use of pde4 inhibitors in a dry powder inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2002000253A true HN2002000253A (es) | 2003-04-07 |
Family
ID=9921954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2002000253A HN2002000253A (es) | 2001-09-12 | 2002-09-11 | Uso de una combinacion de compuestos en un inhalador de polvo seco |
| HN2002000254A HN2002000254A (es) | 2001-09-12 | 2002-10-11 | Uso de compuestos en un inhalador de polvo seco |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2002000254A HN2002000254A (es) | 2001-09-12 | 2002-10-11 | Uso de compuestos en un inhalador de polvo seco |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20030064031A1 (es) |
| EP (1) | EP1427414A1 (es) |
| JP (1) | JP2005505560A (es) |
| KR (1) | KR20040036940A (es) |
| CN (1) | CN1553801A (es) |
| AP (2) | AP2002002623A0 (es) |
| AR (2) | AR036474A1 (es) |
| BG (1) | BG108569A (es) |
| BR (1) | BR0212449A (es) |
| CA (1) | CA2457717A1 (es) |
| CZ (1) | CZ2004310A3 (es) |
| EA (1) | EA006742B1 (es) |
| EC (1) | ECSP045018A (es) |
| EE (1) | EE200400078A (es) |
| GB (1) | GB0122031D0 (es) |
| HN (2) | HN2002000253A (es) |
| HR (1) | HRP20040162A2 (es) |
| HU (1) | HUP0401890A3 (es) |
| IL (1) | IL160380A0 (es) |
| IS (1) | IS7151A (es) |
| MA (1) | MA27062A1 (es) |
| MX (1) | MXPA04002354A (es) |
| NO (1) | NO20041011L (es) |
| NZ (1) | NZ530929A (es) |
| OA (1) | OA12660A (es) |
| PA (2) | PA8554601A1 (es) |
| PE (2) | PE20030509A1 (es) |
| PL (1) | PL368736A1 (es) |
| SK (1) | SK1272004A3 (es) |
| SV (2) | SV2004001227A (es) |
| TN (1) | TNSN04040A1 (es) |
| TW (1) | TW200602054A (es) |
| WO (2) | WO2003022275A1 (es) |
| ZA (1) | ZA200401002B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040176391A1 (en) * | 2002-12-31 | 2004-09-09 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| WO2007036029A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Aerosol powder formulation comprising sieved lactose |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| TR200909788A2 (tr) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu |
| AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
| KR20150076005A (ko) | 2013-12-26 | 2015-07-06 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| CU20170007A7 (es) | 2014-08-06 | 2017-06-05 | Pfizer | Compuestos de imidazopiridazina |
| CN111249260B (zh) * | 2014-09-15 | 2023-01-10 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004974A (en) * | 1995-06-06 | 1999-12-21 | Pfizer Inc | Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19835346A1 (de) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
-
2001
- 2001-09-12 GB GBGB0122031.8A patent/GB0122031D0/en not_active Ceased
-
2002
- 2002-09-02 OA OA1200400071A patent/OA12660A/en unknown
- 2002-09-02 WO PCT/IB2002/003599 patent/WO2003022275A1/en not_active Application Discontinuation
- 2002-09-02 IL IL16038002A patent/IL160380A0/xx unknown
- 2002-09-02 JP JP2003526404A patent/JP2005505560A/ja not_active Withdrawn
- 2002-09-02 NZ NZ530929A patent/NZ530929A/en unknown
- 2002-09-02 WO PCT/IB2002/003598 patent/WO2003022279A1/en not_active Application Discontinuation
- 2002-09-02 EA EA200400301A patent/EA006742B1/ru not_active IP Right Cessation
- 2002-09-02 BR BR0212449-1A patent/BR0212449A/pt not_active IP Right Cessation
- 2002-09-02 CA CA002457717A patent/CA2457717A1/en not_active Abandoned
- 2002-09-02 EP EP02767763A patent/EP1427414A1/en not_active Withdrawn
- 2002-09-02 PL PL02368736A patent/PL368736A1/xx not_active Application Discontinuation
- 2002-09-02 HU HU0401890A patent/HUP0401890A3/hu unknown
- 2002-09-02 MX MXPA04002354A patent/MXPA04002354A/es not_active Application Discontinuation
- 2002-09-02 CZ CZ2004310A patent/CZ2004310A3/cs unknown
- 2002-09-02 SK SK127-2004A patent/SK1272004A3/sk not_active Application Discontinuation
- 2002-09-02 KR KR10-2004-7003619A patent/KR20040036940A/ko active IP Right Grant
- 2002-09-02 EE EEP200400078A patent/EE200400078A/xx unknown
- 2002-09-02 CN CNA028178874A patent/CN1553801A/zh active Pending
- 2002-09-05 US US10/236,551 patent/US20030064031A1/en active Pending
- 2002-09-05 US US10/236,228 patent/US20030064034A1/en not_active Abandoned
- 2002-09-10 AR ARP020103427A patent/AR036474A1/es unknown
- 2002-09-10 AR ARP020103426A patent/AR036473A1/es unknown
- 2002-09-10 PE PE2002000893A patent/PE20030509A1/es not_active Application Discontinuation
- 2002-09-10 PE PE2002000894A patent/PE20030443A1/es not_active Application Discontinuation
- 2002-09-11 TW TW094130352A patent/TW200602054A/zh unknown
- 2002-09-11 HN HN2002000253A patent/HN2002000253A/es unknown
- 2002-09-12 PA PA20028554601A patent/PA8554601A1/es unknown
- 2002-09-12 AP APAP/P/2002/002623A patent/AP2002002623A0/en unknown
- 2002-09-12 SV SV2002001227A patent/SV2004001227A/es not_active Application Discontinuation
- 2002-09-12 PA PA20028554701A patent/PA8554701A1/es unknown
- 2002-09-12 AP APAP/P/2002/002624A patent/AP2002002624A0/en unknown
- 2002-09-12 SV SV2002001226A patent/SV2004001226A/es not_active Application Discontinuation
- 2002-10-11 HN HN2002000254A patent/HN2002000254A/es unknown
-
2004
- 2004-02-06 ZA ZA200401002A patent/ZA200401002B/en unknown
- 2004-02-09 BG BG108569A patent/BG108569A/bg unknown
- 2004-02-13 IS IS7151A patent/IS7151A/is unknown
- 2004-02-19 HR HR20040162A patent/HRP20040162A2/xx not_active Application Discontinuation
- 2004-02-26 MA MA27550A patent/MA27062A1/fr unknown
- 2004-03-10 NO NO20041011A patent/NO20041011L/no not_active Application Discontinuation
- 2004-03-10 TN TNP2004000040A patent/TNSN04040A1/fr unknown
- 2004-03-12 EC EC2004005018A patent/ECSP045018A/es unknown
-
2005
- 2005-06-13 US US11/152,741 patent/US20050232871A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2002000253A (es) | Uso de una combinacion de compuestos en un inhalador de polvo seco | |
| ES2316571T3 (es) | Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria. | |
| FI3125875T3 (fi) | Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon | |
| CR6937A (es) | Nuevo polvo inhalable conteniendo tiotropium | |
| IT1255040B (it) | Forma di ciclosporina adatta alla somministrazione per via polmonare eprocedimento di preparazione. | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| ECSP055855A (es) | Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato | |
| CS35292A3 (en) | Medicaments used for treating asthma by inhaling | |
| RU2007124795A (ru) | Медицинский продукт, содержащий лекарственное средство на основе глюкагоноподобного пептида, предназначенное для легочной ингаляции | |
| KR19990071975A (ko) | 신규한복합조성물 | |
| NO20024973D0 (no) | Farmasöytiske formuleringer for törr pulver inhalatorer | |
| NZ593695A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| JO3102B1 (ar) | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة | |
| WO2006008517A3 (en) | Use of dry powder compositions for pulmonary delivery | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| WO2004012653A3 (en) | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof | |
| BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
| PE20020793A1 (es) | Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio | |
| RU2012156256A (ru) | Факторы трилистника (tff) для лечения хронических заболеваний легких | |
| CZ287114B6 (en) | Therapeutic preparation in the form of aerosol and use of gas mixture | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| EP0919229A3 (en) | Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation | |
| DOP2002000454A (es) | Uso de una combinacion de compuesto en un inhalador de polvo seco. | |
| Alqarni et al. | Cost Effectiveness And Efficiency Among Three Most Common Aerosol Delivery Devices | |
| CN201409484Y (zh) | 挥发性药物口罩 |